<DOC>
	<DOCNO>NCT00346281</DOCNO>
	<brief_summary>This first study investigate safety 32P BioSilicon patient advance , unresectable pancreatic cancer also receive standard intravenous gemcitabine chemotherapy . The secondary aim study assess implantation procedure , localisation 32P BioSilicon , tumour response survival parameter . Tumours targetted 32P BioSilicon hypothesize show reduction tumour volume low radioactivity dose deliver intratumourally , incidence side effect associate treatment expect low . Prologation survival improve quality life could favourable outcomes investigational product .</brief_summary>
	<brief_title>32P BioSiliconTM Addition Gemcitabine Pancreatic Cancer</brief_title>
	<detailed_description>This open label , Phase IIa safety study recruit 15 patient least two site . All patient 32P BioSilicon implant pancreatic tumour single implant , use endoscopic ultrasound . The study examine safety inject activity equivalent absorb dose 100 Gy ( consider initial low risk radioactivity level ) , administer intratumourally patient pancreatic cancer . All patient receive gemcitabine treatment within 2 week prior within 3 day implantation . Any dose adjustment gemcitabine treatment make accord clinical judgement oncologist team make accordance current approve prescribing receommendations . Implantation 32P BioSilicon perform endoscopically trained endoscopist nuclear medicine physician . The 32P BioSilicon prepare designated personnel licence handle radioactive product radioactive waste handle manage per institution 's guideline compliance local regulatory requirement . Bremsstrahlung image perform post implantation preliminary indication localisation implant 32P BioSiliconTM . Assessments perform haematology , biochemistry , CA19-9 marker , performance status adverse event observe report graded accord CTCAE . To minimise inter-observer variation , patient assess investigator throughout study . Tumour assessment tumour volume calculation perform designated radiologist independent study . To standardise , CT scan perform accord agree scan protocol image capture DICOM format site assessment independent radiologist . Tumour response evaluate target tumour use RECIST . Pain assessment use Brief Pain Inventory ( BPI ) pain score record patient . Patients clinically and/or radiologically stable respond disease option continue gemcitabine , discretion investigator . Following discontinuation study , patient follow progression-free , overall survival . A Data Monitoring Committee review study data regular teleconference throughout study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically prove locally advanced metastatic adenocarcinoma pancreas Advanced pancreatic disease , amenable surgical resection Measurable disease CT scan , tumour burden equivalent diameter le 3cm great 6cm ECOG Performance status 0 2 Life expectancy least three month Laboratory parameter : Hb great equal 10 g/dl Platelets great equal 100,000 mm3 ANC great equal 1500/mm3 Bilirubin &lt; 1.3 x ULN Alkaline phosphatase &lt; 5 x ULN Transaminases &lt; 5 x ULN Creatinine &lt; 1.5 x ULN Prothrombin ( PT ) partial thromboplastin time ( PTT ) within normal range Serum calcium within normal range All patient reproductive potential must agree use effective barrier method contraception study six month follow termination treatment . Male female patient age 18 provide write informed consent Any previous treatment 32 Phosphorus 32P BioSiliconTM Any prior radiotherapy pancreatic cancer Use investigational agent time enrolment , within 30 day five halflives enrolment , whichever long History hypersensitivity study product product similar chemical structure ( i.e . silicon phosphorous ) History malignancy organ system , treat untreated , within past five year whether evidence local recurrence metastasis , exception localise basal cell carcinoma skin situ cervical carcinoma Pregnant lactate woman Significant tumour relate pain analgesic intervention incorporate epidural EUS plan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>unresectable pancreatic cancer</keyword>
	<keyword>brachytherapy</keyword>
	<keyword>32P</keyword>
	<keyword>BioSilicon</keyword>
	<keyword>locally advanced</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>intratumourally</keyword>
	<keyword>unresectable</keyword>
</DOC>